期刊文献+

Ph^+急性淋巴细胞白血病与慢性粒细胞白血病急淋变的临床特征分析 被引量:4

Analysis of clinical characters of Ph^+ ALL and lymphoid blast crisis CML
下载PDF
导出
摘要 目的比较Ph+急性淋巴细胞白血病(ALL)与慢性粒细胞白血病(CML)急淋变的临床特征。方法回顾性分析Ph+ALL患者24例和CML急淋变患者28例的临床资料,比较两组患者的临床资料、细胞免疫表型分析结果以及临床疗效。结果 CML急淋变组肝肿大和脾脏肿大比例显著高于Ph+ALL组(P<0.05或P<0.01)。CML急淋变组WBC>10×109/L比例显著高于Ph+ALL组(P<0.05)。治疗前两组融合基因拷贝数差异无统计学意义(P>0.05)。16例Ph+ALL患者治疗后达到缓解,Bcr/abl融合基因拷贝数平均(0.4±0.1),10例CML急淋变患者达到血液缓解,Bcr/abl融合基因拷贝数平均(50.1±15.4),两组比较差异有高度统计学意义(P<0.01)。Ph+ALL组CR发生率显著高于CML急淋变组(P<0.05),平均生存率显著长于CML急淋变组(P<0.01)。结论 Ph+ALL与CML急淋变具有不同的临床特征和不同的遗传性特征。Ph+ALL诱导完全缓解后,Ph染色体呈阴性,而CML急淋变诱导缓解后Ph染色体仍然存在。Ph+ALL完全缓解率高于CML急淋变患者,平均生存时间长于CML急淋变患者。 Objective To analyze clinical characters of Ph+ALL and lymphoid blast crisis CML. Methods Clinical data of 24 cases with Ph+ALL and 28 cases with lymphoid blast crisis CML were retrospectively analyzed. Clinical data, cell phenotype analysis results and clinical efficacy were compared between two groups. Results Proportions of enlargement of the liver and enlargement of the spleen of lymphoid blast crisis CML group were significantly higher than Ph+ALL group(P〈0.05 or P〈0.01). The proportion of WBC10×10°/L of lymphoid blast crisis CML was higher than Ph^+ALL group(P0.05). Before treatment, the fusion gene copy number showed no difference between two groups(P〉0.05). Sixteen cases of Ph^+ALL patients achieved CR, with Bcr/abl fusion gene copy number average(0.4±0.1);10 cases of lymphoid blast crisis CML group achieved CR, with Bcr/abl fusion gene copy number average(50.1±15.4). There was sig nificant difference between two groups(P〈0.01). The incidence cases of Ph+ALL patients achieved CR, which was higher than lymphoid blast crisis CML group(P〈0.05). The average survival rate of Ph+ALL group was significantly longer than the lymphoid blast crisis CML group(P〈0.01). Conclusion Ph+ALL shows different clinical characters and cell phenotype compared with lymphoid blast crisis CML. Ph^+ALL induced after complete remission, Ph chromosome were negative, but CML after becoming urgent to drench induced ease, Ph chromosome still exists. Ph^+ALL complete response rate is higher than the CML rush drench patients, and the average survival time is longer than the CML anxious patients
出处 《中国现代医生》 2014年第34期35-38,共4页 China Modern Doctor
基金 浙江省宁波市科技局课题(2010A610055)
关键词 Ph+急性淋巴细胞白血病 慢性粒细胞白血病急淋变 细胞免疫表型分析 Ph^+ALL Lymphoid blast crisis CML Cell phenotype analysis
  • 相关文献

参考文献16

  • 1苗真,甘思林,邢海洲,刘延方,谢新生,程远东,孙玲,万鼎铭,孙慧.酪氨酸激酶抑制剂联合化疗治疗Ph阳性急性淋巴细胞白血病的临床观察[J].肿瘤基础与临床,2014,27(2):119-121. 被引量:1
  • 2张越峰,陈志妹,楼基余,倪万茂,王云贵,孟海涛,佟红艳,钱文斌,金洁.Ph染色体阳性的成人急性淋巴细胞白血病临床分析[J].中华血液学杂志,2011,32(12):814-818. 被引量:11
  • 3Yanada M, Takeuehi J,Sugiura I,et al. High complete re- mission rate and premising outcome by combination of I- matinib and chemotherapy for newly diagnosed BCR- ABL-Positive acute lymphoblastic leuke-mia : a phase 11 study by the Japan adult leukemia study group[J]. Jourual of Clinical Oncology, 2006,24 (3) : 460-466.
  • 4Lee HJ,Thompson JE,Wang ES,et al. Philadelphia chro- mosome-positive acute lymphoblastic leukemia[J]. Cancer, 2011,117 (8) : 1583-1594.
  • 5Wassmann B ,Pfeifer H,Scheuring UJ,et al. Early prediction of response in patients with relapsed or refractory Philadel- phia chromosome positive acute lymphoblastie leukemia (Ph^+ALL) treated with imatinib mesylate (Glivec)[J]. Blood,2004,103 (4) : 1495-1498.
  • 6Hernandez JM, Granada I, Sole F, et al. From convention- al cytogenetics to microarrays. Fifty years of Philadelphia chromosome[J]. Mad Clin (Sarc), 2011,137 (5) : 221-229.
  • 7Druker BJ,Sawyers CL,Kantarjian H,et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lym- phoblastic lekemia with the Philadelphia chromosome[J]. N Engl J Med,2004,344(14) : 1038-1042.
  • 8Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lym- phoblastic leukemia(Ph^+ ALL)[J]. Blood,2006,108 (5) : 1469- 1477.
  • 9Druker B J, Guilhot F, O'Brien SG, et al. Five-year fol- low-up of patients receiving imatinib for chronic myeloid leukemia[J]. N Engl J Med, 2006,355 (23) : 2408 -2417.
  • 10曹旭东,孙续国,宋敬敬,苏桂新,李小亮,丁红梅,刘金平,黎小沛.微流控芯片单细胞分析慢性粒细胞白血病患者粒细胞表达髓过氧化物酶[J].天津医科大学学报,2014,20(2):157-158. 被引量:5

二级参考文献39

  • 1邱镜滢,朱伟,张艳,陈珊珊,江滨,史惠琳,师岩,何琦,党辉,王德炳,陆道培.Ph染色体阳性急性白血病细胞遗传学及临床研究[J].中国实验血液学杂志,2005,13(3):358-363. 被引量:14
  • 2程介克,黄卫华,王宗礼.单细胞分析的研究[J].色谱,2007,25(1):1-10. 被引量:4
  • 3Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of Imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias [J]. Blood, 2002, 100(6) : 1965-1971.
  • 4Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic lekemia with the Philadelphia chromosome [J]. N Engl J Med, 2004,344(14) : 1038-1042.
  • 5Wassmann B, Pfeifer H, Scheuring U J, et al. Early prediction of response in patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastie leukemia (Ph+ALL) treated with imatinib mesylate (Glivec) [J]. Blood, 2004,103 (4) : 1495-1498.
  • 6Hoelzer D, Gokbuget N. New approaches to acute lymphoblastic leukemia in adults: Where do we go? [J]. Semin Oncol, 2000,27(5) :540-559.
  • 7Radich JP. Philadelphia chromosome-positive acute lymphocytic leukemia [J]. Hematol Oncol Clin North Am, 2001,15 (1): 21-36.
  • 8Delannoy A, Delabesse E, Lheritier V, et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: Results of the GRAALL AFR09 study [J]. Leukemia, 2006,20(9) : 1526-1532.
  • 9Thomas DA. Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges. Hematology Am Soc Hemato! Educ Program, 2007:435-443.
  • 10Ottmann OG, Druker BJ,Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chro- mosome-positive acute lymphoid leukemias. Blood, 2002, 100 : 1965-1971.

共引文献17

同被引文献49

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部